Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy

BACKGROUND: C.E.R.A. (Continuous Erythropoietin Receptor Activator) is an innovative agent with unique erythropoietin receptor activity and prolonged half-life. This study evaluated C.E.R.A. once weekly (QW) or once every 3 weeks (Q3W) in patients with anemia and advanced non-small cell lung cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirsh, Vera, Glaspy, John, Mainwaring, Paul, Manegold, Christian, Ramlau, Rodryg, Eid, Joseph E
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1831793/
https://www.ncbi.nlm.nih.gov/pubmed/17341293
http://dx.doi.org/10.1186/1745-6215-8-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1831793/
https://www.ncbi.nlm.nih.gov/pubmed/17341293
http://dx.doi.org/10.1186/1745-6215-8-8

Ejemplares similares